Article info

Download PDFPDF

Original research
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

Authors

  1. Correspondence to Dr Aung Naing; anaing{at}mdanderson.org
View Full Text

Citation

Naing A, Eder JP, Piha-Paul SA, et al
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors

Publication history

  • Accepted July 6, 2020
  • First published August 24, 2020.
Online issue publication 
August 24, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.